KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other Accumulated Expenses (2016 - 2018)

Alnylam Pharmaceuticals filings provide 6 years of Other Accumulated Expenses readings, the most recent being $23.6 million for Q4 2018.

  • Quarterly Other Accumulated Expenses rose 117.66% to $23.6 million in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $23.6 million through Dec 2018, up 117.66% year-over-year, with the annual reading at $23.6 million for FY2018, 117.66% up from the prior year.
  • Other Accumulated Expenses hit $23.6 million in Q4 2018 for Alnylam Pharmaceuticals, up from $10.9 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $25.4 million in Q1 2014 and bottomed at $3.8 million in Q4 2014.
  • Average Other Accumulated Expenses over 5 years is $13.5 million, with a median of $11.7 million recorded in 2016.
  • The largest annual shift saw Other Accumulated Expenses surged 154.34% in 2016 before it dropped 14.02% in 2017.
  • Alnylam Pharmaceuticals' Other Accumulated Expenses stood at $3.8 million in 2014, then surged by 30.38% to $5.0 million in 2015, then soared by 154.34% to $12.6 million in 2016, then dropped by 14.02% to $10.9 million in 2017, then surged by 117.66% to $23.6 million in 2018.
  • Per Business Quant, the three most recent readings for ALNY's Other Accumulated Expenses are $23.6 million (Q4 2018), $10.9 million (Q4 2017), and $12.6 million (Q4 2016).